Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.48%.

  • ImmunityBio's Return on Invested Capital fell 7800.0% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year decrease of 7800.0%. This contributed to the annual value of 25.91% for FY2023, which is 232300.0% up from last year.
  • Per ImmunityBio's latest filing, its Return on Invested Capital stood at 0.48% for Q3 2025, which was down 7800.0% from 1.17% recorded in Q2 2025.
  • ImmunityBio's 5-year Return on Invested Capital high stood at 1.74% for Q3 2021, and its period low was 2.18% during Q1 2025.
  • Moreover, its 5-year median value for Return on Invested Capital was 1.17% (2022), whereas its average is 0.99%.
  • As far as peak fluctuations go, ImmunityBio's Return on Invested Capital tumbled by -722900bps in 2021, and later skyrocketed by 6600bps in 2025.
  • ImmunityBio's Return on Invested Capital (Quarter) stood at 1.55% in 2021, then grew by 1bps to 1.57% in 2022, then grew by 10bps to 1.72% in 2023, then fell by -27bps to 1.25% in 2024, then tumbled by -62bps to 0.48% in 2025.
  • Its Return on Invested Capital was 0.48% in Q3 2025, compared to 1.17% in Q2 2025 and 2.18% in Q1 2025.